Newly Developed Mobile Phone Device Reads ELISA Plates
|
By LabMedica International staff writers Posted on 17 Aug 2015 |

Image: The new miniature ELISA microplate reader device is created with a 3-D printer and attaches to a smartphone, enabling clinicians to perform lower-cost rapid diagnostic ELISA tests at point-of-care, including in many resource-poor or field settings (Photo courtesy of UCLA).
A multidisciplinary team of scientists and clinicians have developed a handheld smartphone-based device that can quickly read standard 96-well microplates with the same level of accuracy as the platforms commonly used in central clinical laboratories. The device, made by 3-D printing, attaches to the smartphone.
The research team from the University of California Los Angeles (UCLA; Los Angeles, CA, USA), led by Prof. Aydogan Ozcan along with Prof. Dino Di Carlo and Prof. Omai Garner, developed the ELISA reader to enable clinicians to perform these tests at lower cost and with greater flexibility for testing at point-of-care (POC), including in many resource-poor or field settings. “It is quite important to have these kinds of mobile devices, especially for administering medical tests that are usually done in a hospital or clinical laboratory,” said Prof. Ozcan, “This mobile platform can be used for point-of-care testing, screening populations for particular diseases, or tracking vaccination campaigns in most resource-poor settings.”
ELISA testing is most commonly performed with the standard 96-well transparent plastic plates that resemble honeycombs. The new device illuminates the plate with an array of light-emitting diodes (LEDs). The light projected through each well is collected by 96 individual plastic optical fibers. The smartphone transmits the resulting images to UCLA servers through a custom-designed app. The images are then analyzed by a machine-learning algorithm and the results are sent back to the phone for viewing within about 1 minute for the entire 96-well plate.
This mobile platform was compared with the standard FDA-approved well-plate readers at a UCLA clinical microbiology laboratory. The comparison included ELISA tests for mumps, measles, and herpes simplex viruses 1 and 2. Of a total of 571 patient samples, the mobile platform achieved 99.6% accuracy in diagnosing mumps, 98.6% for measles, and 99.4% each for herpes simplex 1 and 2.
“Our team is focused on developing biomedical technologies that work with mobile platforms to assist with on-site testing and health-care in disadvantaged or rural areas,” said Mr. Berg. Prof. Di Carlo added, “We are always looking toward the next innovation, and are looking to adapt the basic design of this ELISA cellphone reader to create smartphone-based quantified readers for other important medical tests.”
The work, by Berg B, et al, was reported online July 9, 2015, in the American Chemical Society journal ACS Nano.
Related Links:
UCLA
California NanoSystems Institute (at UCLA and UCSB)
The research team from the University of California Los Angeles (UCLA; Los Angeles, CA, USA), led by Prof. Aydogan Ozcan along with Prof. Dino Di Carlo and Prof. Omai Garner, developed the ELISA reader to enable clinicians to perform these tests at lower cost and with greater flexibility for testing at point-of-care (POC), including in many resource-poor or field settings. “It is quite important to have these kinds of mobile devices, especially for administering medical tests that are usually done in a hospital or clinical laboratory,” said Prof. Ozcan, “This mobile platform can be used for point-of-care testing, screening populations for particular diseases, or tracking vaccination campaigns in most resource-poor settings.”
ELISA testing is most commonly performed with the standard 96-well transparent plastic plates that resemble honeycombs. The new device illuminates the plate with an array of light-emitting diodes (LEDs). The light projected through each well is collected by 96 individual plastic optical fibers. The smartphone transmits the resulting images to UCLA servers through a custom-designed app. The images are then analyzed by a machine-learning algorithm and the results are sent back to the phone for viewing within about 1 minute for the entire 96-well plate.
This mobile platform was compared with the standard FDA-approved well-plate readers at a UCLA clinical microbiology laboratory. The comparison included ELISA tests for mumps, measles, and herpes simplex viruses 1 and 2. Of a total of 571 patient samples, the mobile platform achieved 99.6% accuracy in diagnosing mumps, 98.6% for measles, and 99.4% each for herpes simplex 1 and 2.
“Our team is focused on developing biomedical technologies that work with mobile platforms to assist with on-site testing and health-care in disadvantaged or rural areas,” said Mr. Berg. Prof. Di Carlo added, “We are always looking toward the next innovation, and are looking to adapt the basic design of this ELISA cellphone reader to create smartphone-based quantified readers for other important medical tests.”
The work, by Berg B, et al, was reported online July 9, 2015, in the American Chemical Society journal ACS Nano.
Related Links:
UCLA
California NanoSystems Institute (at UCLA and UCSB)
Latest Immunology News
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







